Last reviewed · How we verify

Viriom — Portfolio Competitive Intelligence Brief

Viriom pipeline: 0 marketed, 0 filed, 1 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 2 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
AV5080 AV5080 phase 3 Nucleoside analog antiviral Viral RNA-dependent RNA polymerase Infectious Disease / Virology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  2. Estetra · 1 shared drug class
  3. French National Agency for Research on AIDS and Viral Hepatitis · 1 shared drug class
  4. Göteborg University · 1 shared drug class
  5. Hoffmann-La Roche · 1 shared drug class
  6. Merck Sharp & Dohme LLC · 1 shared drug class
  7. MinaPharm Pharmaceuticals · 1 shared drug class
  8. Ain Shams University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Viriom:

Cite this brief

Drug Landscape (2026). Viriom — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/viriom. Accessed 2026-05-14.

Related